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Abstract
Subungual melanoma (SUM) is a subtype of acral melanoma. Its incidence in 
dark phototypes, Hispanics and Asians, is around 20% and accounts for 50% of 
acral melanomas. It is an infrequent subtype in Caucasians representing only 3%. 
Subungual melanoma arises from dormant melanocytes in the nail matrix and 
exceptionally from melanocytes in the nail bed. In its initial phases of radial growth, 
it presents as longitudinal melanonychia. The differential diagnoses are melanocytic 
activation (racial, traumatic), nail matrix nevi, and lentigos. Prognosis depends on 
Breslow depth at diagnosis. For in situ melanoma, treatment consists of conservative 
surgical removal of the nail unit with 5 mm margins.
Keywords: subungual melanoma, longitudinal melanonychia, acral melanoma,  
nail melanoma
1. Introduction
Subungual melanoma (SUM) is a subtype of acral lentiginous melanoma. It is a 
rare subtype in Caucasians accounting for 3% of all melanomas. In dark phototypes, 
Hispanics and Asians, it represents 20%, and it is the most frequent malignancy of 
the nail unit [1].
SUM or nail melanoma arises from dormant melanocytes in the nail unit, mainly 
in the nail matrix, and exceptionally in the nail bed.
UV radiation is not considered an important risk factor for this subtype of 
melanoma. Trauma has been a hypothetical etiologic agent. Many patients associate 
direct trauma to the onset of this malignancy, and it has been hypothesized that 
inflammation can cause mutations in melanocytes during trauma-induced prolifer-
ation; but a direct association has not been proven, and it may only be a coincidence 
due to increased attention to a longitudinal melanonychia after trauma [2].
SUM has a long radial growth phase that can last for many years; in this stage it 
presents as longitudinal melanonychia, and the differential diagnosis includes racial 
and traumatic melanocytic activation, nail matrix nevi, and lentigo of the nail unit [3].
Nail plate pigmentation can also be caused by blood and external pigments such 
as silver in argyria. Many drugs cause nail pigmentation by drug deposition or by 
melanocytic activation (minocycline, psoralens, cyclophosphamide, zidovudine). 
Bacterial or fungal infections (Proteus mirabilis, Aspergillus sp., Candida sp., 
Trichophyton rubrum) can cause nail pigmentation; other subungual tumors such 
as epidermoid carcinoma and even a subungual wart can present as longitudinal 
melanonychia [3].
Clues to the diagnosis of melanoma include a single-digit affection, mela-
nonychia wider than 3 mm with a triangular form (this means that the band is 
growing), rapid widening of a longitudinal melanonychia, onset in adulthood 
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(melanoma in children is quite rare), and Hutchinson’s and micro-Hutchinson’s 
sign [4] (Figure 1 and Table 1).
In more advanced stages, SUM causes nail dystrophy, ridging, partial destruction of 
the nail plate, ulceration, bleeding, and total destruction of the nail unit (Figure 2).
SUM affects women and men equally, although some series report a slight pre-
dominance in women. SUM is more common on the dominant hand, and it is more 
frequently reported on the thumbs and on the first finger on both toes [1].
A Age: 40–60 years. Does not rule out in children
African, American, Asian, Hispanics
B Band: brown-black irregular
Blurred borders
>4 mm
C Change: rapid increase in size
No change: failure to improve
D Single digit:
Thumb-hallux-index finger
Dominant hand
Nail dystrophy: ridging ulceration
E Extension—Hutchinson’s sign: pigment on nail folds
Micro-Hutchinson: cuticle pigmentation visible with dermoscopy
F Family or personal history of melanoma
Adapted from [4].
Table 1. ABC rule to suspect SUM.
Figure 1. 
SUM in situ. Longitudinal irregular melanonychia with nail plate ridging.
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SUM is frequently diagnosed in advanced stages, due to a delay in diagnosis by 
healthcare providers not aware of its existence and clinical presentation or due to lack of 
access to medical services. The median Breslow at diagnosis is between 4 and 6 mm [1].
2. Dermoscopy
Dermoscopy of the nail unit is a noninvasive method that can help identify high-
risk features.
Dermoscopy is useful to distinguish blood; subungual hemorrhage has a distinc-
tive pattern of globules with distal streaks, a filamentous end, and red to brown 
or deep purple color. It is important to consider a bleeding tumor and rule out that 
possibility [5].
Figure 2. 
Invasive SUM with Hutchinson’s sign and partial destruction of the nail plate.
Figure 3. 
Dermoscopy of SUM in situ. Irregular multiple heterogenous brown bands with blurred edges and 
microhutchinson’s sign.
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Subungual melanoma should be suspected and ruled out in heterogeneous longi-
tudinal brown or black melanonychias, when bands are irregular in color, thickness, 
and spacing. SUM can also present as a diffuse dark background with barely visible 
lines (Figure 3). When a brown coloration in the background is overlaid by regular, 
parallel, and pigmented lines, the most probable diagnosis is a nevus.
Edge blurring is another sign associated with SUM. Hutchinson’s sign is consid-
ered an indicator of SUM; however, it can also be found in benign nevi. Atypical 
Hutchinson’s sign in SUM is asymmetric and polychromatic, and the pigment is 
distributed in a disorderly fashion. Micro-Hutchinson’s sign is periungual pigmen-
tation invisible to the naked eye and only observed with dermoscopy; it has only 
been described in SUM. Triangular shape of the longitudinal band (wider proxi-
mally than distally) indicates rapid growth [5, 6].
A grayish longitudinal background either alone or overlaid by thin homogenous 
gray lines is suggestive of melanocytic hyperplasia as in lentigo or lentiginoses 
(Laugier-Hunziker syndrome, Leopard syndrome, Peutz-Jeghers-Touraine disease), 
in drug-induced, ethnic, and traumatic nail pigmentation.
Amelanotic SUM is a very difficult diagnosis; in this rare case, the nail plate 
is often partially destroyed by a bleeding, erythematous vegetating tumor. 
Dermoscopy can show areas of remanant pigmentation and vascular disorder: 
irregular vessels and milky-red areas [5].
3. Nail matrix biopsy
Nail matrix biopsy remains essential for diagnosis. Most melanomas arise from 
the distal matrix; by performing dermoscopy of the free edge of the nail plate, it is 
sometimes possible to determine the origin of melanonychia. If the distal matrix is the 
origin of melanonychia, the ventral aspect of the nail plate will be affected, and if the 
proximal nail matrix is the origin, the dorsal aspect of the nail plate will be pigmented.
Figure 4. 
Nail matrix biopsy technique: proximal nail fold flap and exposure of the nail matrix.
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The surgical technique consists in exposing the nail matrix, identifying the ori-
gin of melanonychia, and taking a representative sample of the nail matrix without 
leaving permanent nail dystrophy. This technique is performed under digital block 
anesthesia. First, the nail plate has to be removed, and a flap of the proximal nail 
fold elevated so that the proximal and distal nail matrix is exposed (Figure 4).
Intraoperative dermoscopy of the nail matrix is an effective tool to precisely 
identify the origin of the pigment. A longitudinal matrix biopsy, no more than 
3-mm-wide or a 3-mm-punch biopsy, can be done without risk of dystrophy; a shave 
biopsy of the matrix 1 mm deep is enough to make the diagnosis and lessens the risk 
of permanent dystrophy. There is no need to suture the nail matrix; the nail plate and 
the proximal nail fold are relocated and sutured with a 4-0 nonabsorbable suture.
In cases of invasive SUM, a lateral longitudinal nail biopsy that includes the 
proximal fold, the matrix lateral horn, the nail bed, the plate, and the distal nail fold 
is easier to perform and gives the pathologist enough tissue to make the diagnosis 
and report Breslow depth (Figure 5).
4. Histology
Nail matrix biopsy is still essential for SUM diagnosis. Normal nail matrix has 
between 4 and 14 melanocytes per mm (mean 6.86 cells/mm per mm stretch of nail 
matrix epithelium) [7].
The presence of nests without atypia is distinctive of nevi, especially in a child 
with a well-demarcated, uniformly pigmented, single, longitudinal band [8].
The histologic distinction between a benign subungual pigmented macule (len-
tigo or lentigo-like hyperpigmentation) and an early lesion of SUM can be difficult.
This benign lentigos may histologically only show an increase in melanin 
deposition in keratinocytes, melanocytes, and/or macrophages without prolifera-
tion of melanocytes (melanocytic activation). However, these benign lesions may 
show proliferation of melanocytes as well. The mean density of melanocytes in 
lentigos is around 15.3 cells per 1-mm-stretch nail matrix. There is no confluence of 
melanocytes. Cytologic atypia has to be absent or mild. There is no inflammation 
associated. Pagetoid spread may be present but only focally.
SUM in situ shows a much greater proliferation of melanocytes (mean 58.9 
cells per 1 mm of stretched nail matrix) that ranges from 39 to 136 melanocytes 
per 1 mm of stretched nail matrix. There is at least focal confluence of cells with 
various grades of cytologic atypia: nuclear enlargement, hyperchromatism, irregu-
lar nuclear contours, and prominent nucleolus. Dendrites are thicker and larger. 
Pagetoid spread is found in almost all lesions of SUM, and inflammation in the 
Figure 5. 
Lateral longitudinal nail biopsy.
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epithelial stromal interface is frequent [6, 7]. In some cases of SUM with lentigi-
nous growth of single atypical melanocytes, immunohistochemical stains with 
MELAN-A and HMB-45 may ease the diagnosis.
Invasive SUM has denser proliferation of atypical melanocytes arranged in 
aggregates and sheaths and may lead to nail dystrophy, nail destruction, and 
ulceration.
It can be difficult to measure Clark level and Breslow thickness, because the 
distinction of the onychodermis is not always clear and the underlying phalanx is 
separated by only a thin dermal collagen layer [6].
5. Treatment
SUM in situ must be surgically removed with wide resection of the entire nail 
unit with a 5-mm-wide margin and periosteum depth (Figure 6).
Reconstruction can be performed with the next finger banner flap and a full 
thickness graft, or it heals by the second intention with good functional results [1].
Treatment for invasive SUM is amputation of the phalanx.
Sentinel lymph node biopsy should be performed in SUM with Breslow depth 
>1 mm and in SUM >0.8 mm with ulceration [1, 9–11].
The most important factors for prognosis and survival are Breslow depth, 
ulceration, and nodal status at diagnosis [10, 11].
SUM has the same prognostic factors as other subtypes of melanoma. The 
adverse outcomes associated with SUM are due to delay in diagnosis because of a 
lack in recognition by health professionals and advanced stages at diagnosis.
Figure 6. 
Resection of the nail unit with 5 mm wide margins and periosteum depth.
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